Diabetic patients are more likely to develop alcohol-related steatotic liver disease (SLD) and metabolic diseases, which can raise the risk of gastrointestinal cancer. To create preventative measures and enhance long-term results in this susceptible group, it is essential to comprehend how SLD contributes to carcinogenesis in diabetics. Thus, this study examined the relationship between the incidence of 5 main GI tract malignancies in a large-scale diabetic cohort and recently characterized MASLD and alcohol-related SLD.
4 subgroups were identified from a statewide cohort of 2,616,828 diabetics covered by the Korean National Health Insurance Service between 2015 and 2016: no steatosis (group 1), MASLD alone (group 2), MASLD with high alcohol consumption (group 3), and alcoholic liver disease (group 4). Using cutoff values of 30 and 60, this research evaluated the risk of hepatic steatosis using the fatty liver index.
Up to 2022, this study examined the prevalence of esophagus, stomach, colorectal, biliary, and pancreatic cancers. The adjusted hazard ratios [95% confidence interval] were 1.10 [1.06–1.13], 1.13 [1.10–1.16], 1.10 [1.05–1.16], and 0.88 [0.79–0.97], respectively, for stomach, colorectal, and biliary cancers were higher in group 2 than in group 1 (reference).
In non-drinkers, the probability of hepatic steatosis was strongly connected with all gastrointestinal tract malignancies except esophageal cancer; in light drinkers, it was only significantly correlated with stomach, colorectal, and biliary cancers (ptrend < 0.001). These results emphasize the significance of closely evaluating the risk of gastrointestinal tract cancer in those with metabolic syndrome, diabetes, or steatotic liver disease.
Overall, an increased risk of gastrointestinal tract cancer is linked to MASLD. An elevated risk of stomach, colorectal, and biliary malignancies is linked to the risk of hepatic steatosis. The likelihood of hepatic steatosis raises the risk of gastrointestinal tract malignancies among nondrinkers or light drinkers.
Reference:
Im, S.-G., Shin, C. M., Han, K., Jung, J. H., Choi, J., Jo, H., Lee, H.-K., Jin, E. H., Kang, S. J., Lim, J. H., Choi, Y. J., & Lee, D. H. (2025). Metabolic and alcohol-related steatotic liver disease and gastrointestinal cancer risk in diabetes. Scientific Reports, 15(1), 37224. https://doi.org/10.1038/s41598-025-21005-6
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.